VPR Brands, LP. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VPR Brands, LP. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.62M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.68M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $9.85M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $4.93M | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | $6.22M | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $3.97M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $5.26M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $4.61M | Jun 9, 2020 |
| FY2018 | Dec 31, 2017 | $3.61M | May 6, 2019 |
| FY2017 | Dec 31, 2016 | $1.58M | Apr 18, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.04M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.53M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.88M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $1.64M | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | $2.14M | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $1.69M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.71M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $1.92M | Jun 9, 2020 |
| FY2018 | Dec 31, 2017 | $1.21M | May 6, 2019 |
| FY2017 | Dec 31, 2016 | $480.9K | Apr 18, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.20M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($143.2K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.93M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($203.7K) | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | $127.2K | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | ($563.8K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($1.18M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($973.7K) | Jun 9, 2020 |
| FY2018 | Dec 31, 2017 | ($1.61M) | May 6, 2019 |
| FY2017 | Dec 31, 2016 | ($375.7K) | Apr 18, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.46M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.37M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.67M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($190.5K) | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | $201.9K | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | ($16.8K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($687.4K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $9.5K | Jun 9, 2020 |
| FY2018 | Dec 31, 2017 | ($888.8K) | May 6, 2019 |
| FY2017 | Dec 31, 2016 | ($327.8K) | Apr 18, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2014 | $3.4K | Apr 7, 2016 |
| FY2012 | Dec 31, 2012 | $3.0K | Mar 26, 2013 |
| FY2011 | Dec 31, 2011 | $3.0K | Jul 20, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.50M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.66M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.21M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $1.83M | Apr 19, 2024 |
| FY2020 | Dec 31, 2020 | $1.71M | Apr 15, 2021 |
| FY2020 | Dec 31, 2019 | $2.40M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $1.91M | Jun 9, 2020 |
| FY2018 | Dec 31, 2017 | $2.10M | May 6, 2019 |
| FY2017 | Dec 31, 2016 | $808.6K | Apr 18, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.12M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $274.1K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.48M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($312.4K) | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | ($147.7K) | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | ($69.6K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($1.34M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($227.4K) | Jun 9, 2020 |
| FY2018 | Dec 31, 2017 | ($698.6K) | May 6, 2019 |
| FY2017 | Dec 31, 2016 | ($445.7K) | Apr 18, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2016 | $15.2K | Apr 18, 2018 |
| FY2013 | Dec 31, 2013 | $2.5K | May 7, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.59M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.75M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.19M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $1.63M | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | $1.25M | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $908.3K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.27M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $767.2K | Jun 9, 2020 |
| FY2018 | Dec 31, 2017 | $471.1K | May 6, 2019 |
| FY2017 | Dec 31, 2016 | $970.2K | Apr 18, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.07M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.04M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.58M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $3.95M | Apr 19, 2024 |
| FY2021 | Dec 31, 2021 | $3.37M | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $3.15M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.95M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $1.35M | Jun 9, 2020 |
| FY2017 | Dec 31, 2017 | $1.30M | Apr 18, 2018 |
| FY2017 | Dec 31, 2016 | $1.10M | Apr 18, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.79M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($7.59M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($7.49M) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($10.42M) | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | ($10.21M) | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | ($10.34M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($9.78M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($8.60M) | Jun 9, 2020 |
| FY2018 | Dec 31, 2017 | ($7.63M) | May 6, 2019 |
| FY2017 | Dec 31, 2016 | ($6.01M) | Apr 18, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.3K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.42M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.77M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $22.4K | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | $2.6K | Apr 13, 2023 |
| FY2020 | Dec 31, 2019 | $22.8K | Apr 15, 2021 |
| FY2020 | Dec 31, 2018 | $58.3K | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | $56.6K | Jun 9, 2020 |
| FY2018 | Dec 31, 2016 | $83.8K | May 6, 2019 |
| FY2017 | Dec 31, 2015 | $4.7K | Apr 18, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $419.0K | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $419.0K | Apr 16, 2025 |
| FY2024 | Dec 31, 2022 | $835.0K | Apr 16, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 19, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 19, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Apr 15, 2022 |